{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-005256","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2022-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.867993+00:00","generated_at":"2026-06-27T08:03:36.480129+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbCellera-discovered antibody bebtelovimab receives FDA EUA for COVID-19 treatment","bullets":["Bebtelovimab (LY-CoV1404) authorized for mild-to-moderate COVID-19 in high-risk patients 12+.","Neutralizes Omicron including BA.2 and all known variants; binds rarely mutated spike region.","Second AbCellera antibody from Lilly collaboration; dosage 175 mg IV injection.","U.S. government agreed to buy up to 600,000 doses by March 2022, option for 500,000 more.","CEO Hansen highlights potency; previous antibody bamlanivimab also received EUA."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-005256","json":"https://secwatch.observer/filing/0001564590-22-005256.json","markdown":"https://secwatch.observer/filing/0001564590-22-005256.md","text":"https://secwatch.observer/filing/0001564590-22-005256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022005256/0001564590-22-005256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022005256/abcl-8k_20220211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:03:36.480129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}